Core Viewpoint - Rocket Doctor AI Inc. has increased its non-brokered private placement offering to a maximum of $4.5 million due to high demand, with each unit priced at $0.70 [1] Group 1: Offering Details - The offering has been upsized from its initial announcement on January 9, 2025, and the amended offering document is available on the company's profile and website [2] - All other terms of the offering remain unchanged despite the increase in the maximum gross proceeds [1] Group 2: Company Overview - Rocket Doctor AI Inc. provides AI-powered healthcare solutions designed to enhance accessibility throughout the patient journey, featuring the Global Library of Medicine (GLM) as a key component [4] - The company has empowered over 300 physicians to manage more than 700,000 patient visits, enabling doctors to launch and manage virtual or hybrid practices [5] - The technology aims to reduce administrative burdens, improve care consistency, and enhance physician-patient interactions, particularly targeting underserved communities in Canada and patients on Medicaid and Medicare in the U.S. [6]

Governance evolution follows elimination of major convertible debt, recent funding, and improved capital structure Company advances governance framework aligned with shareholder interests and future listing requirements West Palm Beach, FL, Jan. 16, 2026 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health infrastructure company supporting primary care practices, today announced that it has initiated a formal process to expand its board of directors by adding independent members. ...

MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Digbi Health, the national leader in Precision Biology–based chronic care, today announced peer-reviewed, actuarially validated significant healthcare cost savings for employers. The findings of this multi-year, multi-employer medical claims analysis were published in the prestigious journal Healthcare. The analysis confirms that employers using Digbi Health’s Precision Biology platform can achieve actuarially guaranteed, hard-dollar reductions in med ...

Omada Health FY Conference Summary Company Overview - **Company**: Omada Health (NasdaqGS:OMDA) - **Industry**: Digital Health and Chronic Disease Management - **Mission**: To bend the curve of disease and improve care for chronic disease patients, particularly those with obesity, diabetes, and other related conditions [3][4] Key Highlights Financial Performance - **Revenue**: $257 million for FY 2025, representing a **52% year-over-year growth** [6][26] - **Members Supported**: 886,000 active members [7][26] - **Adjusted Gross Margin**: Upper 60s% for LTM Q3 2025, improved from the 50s% in 2022 [26] - **Adjusted EBITDA Margin**: -2.4% for LTM Q3 2025, improved from nearly -70% in 2022, with the first positive adjusted EBITDA quarter of $2.4 million in Q3 2025 [27] Market Position and Strategy - **Target Market**: Over 20 million Americans covered by Omada's programs through 2,000+ customers, including self-insured employers and health plans [5][18] - **Expansion**: Initially focused on prediabetes and obesity, now expanded to diabetes, hypertension, and musculoskeletal (MSK) care [6][9] - **Growth Drivers**: - Multi-product offerings, including the new GLP-1 Care Track [21] - Customer-driven expansion based on demand for comprehensive care solutions [9][19] Product and Service Offerings - **Care Model**: Combines technology and personalized care to support patients between doctor visits [5][10] - **GLP-1 Care Track**: Launched to provide behavioral support alongside GLP-1 medications, addressing concerns about medication adherence and effectiveness [21][22] - **Engagement Metrics**: Over 55% of members remain engaged after 12 months, and 50% after two years [14][15] Clinical and Economic Outcomes - **Clinical Evidence**: 30 peer-reviewed publications demonstrating the effectiveness of Omada's programs [15][16] - **Economic Value**: Expected ROI of 3-6x in musculoskeletal care, with gross healthcare savings of $1,000-$1,500 per member [16][26] Future Outlook - **Investment Focus for 2026**: Emphasis on AI initiatives and enhancing prescribing capabilities to drive long-term growth and margin expansion [41][42] - **Market Trends**: Increased focus on chronic disease management from government and employers, with potential opportunities in Medicare Advantage [54][56] - **Customer Demand**: Growing interest in combining prescribing with behavioral management for chronic conditions [43][44] Additional Insights - **Customer Relationships**: Strong demand for multi-product solutions, with 75% of new clients opting for more than one condition [52] - **Regulatory Environment**: Positive dialogue with government regarding chronic disease management, indicating potential for future partnerships [54][56] - **Technological Integration**: Use of AI to enhance member experience and operational efficiency, with features like nutritional intelligence agents [38][39] This summary encapsulates the key points from Omada Health's FY conference, highlighting the company's growth, strategic direction, and the evolving landscape of chronic disease management.

On Monday, iRhythm Technologies Inc. (NASDAQ:IRTC) reported preliminary fourth quarter operational highlights.The digital health company anticipates full-year 2025 revenue to exceed the high end of the previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter of 2025.The analysts estimated a consensus of $737.95 million.For fiscal year 2026, iRhythm expects revenue of approximately $870 million to $880 million, up approximately ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Digital health funding spiked in 2025 as investors poured a growing amount of cash into artificial intelligence companies, according to a report released Monday by Rock Health. U.S. digital health startups raised $14.2 billion last year — the highest funding total in the sector since 2022, the venture capital firm and advisory said. In comparis ...

Vancouver, BC, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc.'s (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that the Company has granted an aggregate 75,000 stock options, exercisable at $0.74 per share and valid for a term of three years, and an aggregate 212,148 restricted share units, valid for a term of three years, to consultants of the Company. The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject ...

Core Insights - iRhythm Technologies, Inc. has reported a transformative year in 2025, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time in its history [3] Operational Highlights - The company has recorded strong commercial volumes and is well-positioned for growth in 2026 with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [3] - iRhythm's clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of its Zio LTCM product, which is expected to expand into additional populations and care settings [3] Financial Outlook - For full year 2025, revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025 [7] - The company expects revenue for 2026 to be approximately $870 million to $880 million, representing a year-over-year growth of about 17% to 18%, with an adjusted EBITDA margin of approximately 11.5% to 12.5% [7] Clinical Evidence - Recent real-world evidence from over 1.4 million patients reinforces the clinical superiority of Zio LTCM, with data demonstrating consistent performance in Asian populations and validating successful at-home self-application for earlier detection in at-risk populations [7]

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States Vancouver, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rocker Doctor AI Inc. (the “Company” or “Rocket Doctor AI”) (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) is pleased to announce that it is undertaking a non-brokered private placement of a minimum of 4,285,715 units (the “Units”) of the Company at a price of $0.70 ...

OptimizeRx Corp (NASDAQ:OPRX) is one of the best performing micro cap stocks in 2025. On January 5, Stifel Nicolaus analyst David Grossman reaffirmed a Buy rating on OptimizeRx with a $21 price target. Just days earlier, on December 23, Lake Street analyst Eric Martinuzzi also reiterated a Buy rating on the stock, setting a $24 price target. OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades everything possible/Shutterstock.com On December 17, OptimizeRx Corp (NASDAQ ...